Posted by Michael Wonder on 31 Aug 2020
New hope for Australian leukaemia and lymphoma patients with key treatment option listed on PBS
31 August 2020 - A key new cancer treatment has just become more accessible for Australians fighting specific forms of leukaemia and lymphoma, thanks to the Morrison Government’s listing of Calquence on the PBS.
On 1 September, Calquence (acalabrutinib) will be listed on the PBS for the first time for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
Furthermore, access to Keytruda (pembrolizumab) will be expanded on the PBS to include treatment of relapsed or refractory primary mediastinal B-cell lymphoma. This is a rare type of lymphoma that largely affects young adults and there is currently a need for newer targeted therapies for this condition.
